A Phase II Trial of single agent CABOZANTINIB in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy (ANZUP 1802)

  • Gurney, Howard (Primary Chief Investigator)
  • Chapman, Nicola (Research Coordinator)
  • Cunningham, Jacob (Research Coordinator)
  • Butala, Radhika (Research Coordinator)

Project: Other

Project Details

StatusFinished
Effective start/end date14/03/19 → 13/03/24